Related Experiment Videos

CD4 immunoadhesin, but not recombinant soluble CD4, blocks syncytium formation by human immunodeficiency virus type

I Sekigawa1, S M Chamow, J E Groopman

  • 1Department of Medicine, New England Deaconess Hospital, Harvrd Medical School, Boston, Massachusetts 02215.

Journal of Virology
|October 1, 1990
PubMed

Insights

Recombinant soluble CD4 (rCD4) and its fragments inhibit HIV-1 syncytia formation. However, only CD4-immunoglobulin G blocks HIV-2 syncytia, indicating distinct cell fusion mechanisms between HIV-1 and HIV-2.

Area of Science:

  • Virology
  • Immunology

Background:

  • Recombinant soluble CD4 (rCD4) is known to inhibit HIV-1 and HIV-2 infection in vitro.
  • Syncytium formation is a key indicator of viral spread and cell fusion in HIV infection.

Purpose of the Study:

  • To investigate the differential effects of rCD4, the V1V2 fragment of CD4, and CD4-immunoglobulin G on syncytium formation mediated by HIV-1 and HIV-2.
  • To elucidate differences in cell fusion processes between HIV-1 and HIV-2.

Main Methods:

  • In vitro characterization of syncytium formation in lymphoid cells infected with HIV-1 or HIV-2.
  • Treatment with rCD4, V1V2 fragment of CD4, and CD4-immunoglobulin G.

Main Results:

  • All tested molecules (rCD4, V1V2, CD4-IgG) effectively blocked HIV-1-mediated syncytium formation.
  • Only CD4-immunoglobulin G inhibited HIV-2-mediated syncytium formation.
  • rCD4 and V1V2 fragment of CD4 enhanced HIV-2-mediated syncytium formation.

Conclusions:

  • HIV-1 and HIV-2 exhibit distinct cell fusion mechanisms.
  • CD4-based inhibitors show differential efficacy against HIV-1 and HIV-2 syncytium formation.

Related Concept Videos